Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2024-09-25 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
关于变更签字注册会计师的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the change of the signing certified public accountant for the company's 2024 financial audit. It details the replacement of one signing auditor with another and confirms the independence and integrity of the new auditor. The document does not contain any financial statements or audit results itself, but rather informs about a personnel change related to the audit process. It is not a full audit report, annual report, or financial statement. Given the nature of the content, it fits best under 'Audit Report / Information' (AR) as it relates to audit personnel and audit-related information, but since it is specifically about a change in signing auditors, it is a standalone audit-related announcement. The document length is short and it is not merely announcing the publication of a report, so it is not a Report Publication Announcement (RPA). Therefore, the classification is AR with high confidence. FY 2024
2024-09-25 Chinese
投资者关系活动记录表
Investor Presentation Classification · 95% confidence The document is titled as an "投资者关系活动记录表" which translates to "Investor Relations Activity Record." It details an investor online communication meeting held on August 29-30, 2024, including questions and answers about the company's R&D budget, product pipeline, sales performance, production capacity, and cost structure. The content is a record of an investor relations event rather than a formal financial report or earnings release. It does not contain financial statements or earnings highlights but rather a Q&A session with management. This fits the category of an Investor Presentation (IP) or similar investor communication. Given the detailed Q&A format and focus on investor relations activities, the best fit is Investor Presentation (IP). The document length is short (2305 characters), but it is not merely an announcement or a certification, so it is not RPA or RNS. Confidence is high due to clear investor relations context and detailed content.
2024-09-01 Chinese
股权激励计划限制性股票解除限售公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the lifting of restrictions on certain shares under a stock incentive plan. It details the number of shares becoming tradable, the shareholders involved, their roles, and the reasons for lifting the restrictions. It also includes tables showing the shareholding changes and confirms compliance with regulatory requirements. There is no financial performance data, earnings information, or management discussion. The document is a formal disclosure about share transactions related to restricted stock becoming unrestricted, which fits the category of Transaction in Own Shares (POS).
2024-08-28 Chinese
持股5%以上股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the results of a shareholder's reduction in shareholding. It details the shareholder's name, shareholding percentages before and after the reduction, the number of shares reduced, the method and period of reduction, and confirms that the reduction plan was completed as planned. The document is short (885 characters) and focuses on shareholding changes by a significant shareholder (over 5%). It is not a financial report, earnings release, or management discussion. It fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2024-08-28 Chinese
第四届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a meeting resolution announcement from the Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The agenda includes approval of the company's 2024 semi-annual report and a special report on the use of raised funds, both of which are published separately on the Beijing Stock Exchange website. The document itself does not contain the financial report or detailed financial data but rather announces the resolutions passed in the Supervisory Board meeting. The document length is short (1296 characters) and it references reports published elsewhere, indicating it is not the report itself but an announcement of meeting resolutions. This fits best with the category of Regulatory Filings (RNS), as it is a formal regulatory announcement that does not fit other specific categories like Interim Report (IR) or Annual Report (10-K).
2024-08-27 Chinese
2024年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "半年度报告摘要" which translates to "Half-Year Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, and other financial metrics for the half-year period. It also includes company business descriptions, shareholding structure, and management assurances about the report's accuracy. The document length is 7230 characters, which is substantial and contains actual financial data and analysis, not just an announcement or certification. The content matches the characteristics of an Interim / Quarterly Report (IR), as it covers a period shorter than a full fiscal year and provides comprehensive financial information and business overview. Therefore, the correct classification is IR (Interim / Quarterly Report). H1 2024
2024-08-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.